Acuitas Therapeutics is the leader in lipid nanoparticle (LNP) delivery, the critical technology behind the mRNA COVID-19 vaccines. With not one, but two LNP formulations in commercially approved products, Acuitas is the only company in its field to achieve this milestone.
Acuitas engaged HDMZ to amplify its broader story and showcase its expertise beyond a single application. The program focused on establishing Acuitas’s authoritative voice in key media, highlighting its unique approach to LNP engineering and its crucial contributions to a wide array of partner programs.
